ZYME
ZymeworksDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
Current thesis
Positive clinical readouts and a strategic partner deal de-risk the pipeline, accelerate cash inflows, and justify meaningful re-rating toward the high-30s per share on deal multiples and peer comps.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +6.4.
What can break
Clinical setbacks or the need for dilutive financing compress valuation; absent catalytic BD, downside to the high-teens is plausible given binary trial risk and limited near-term revenues.
Momentum
38
Value
41
Sentiment
58
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $27.49 · Bull $34.99 · Bear $17.49
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-26 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-03
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $39.10
Why
Momentum38 · Δ7d +0.1
Value41 · Δ7d +0.0
Sentiment58 · Δ7d +6.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
38
34% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-32.7
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.2
Sentiment
58
33% active weight
Current posture
7d trendImproving
Δ7d
+6.4
Δ21d
+6.2
Why this grade
Composite grade D. Momentum 37.7 / Value 41.1 / Sentiment 57.8
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$1.77B
Beta
1.25
Shares Out
75.41M
P/E (TTM) · Derived
-21.9
P/S (TTM)
14.18
P/FCF (TTM) · Derived
-26.92
Rev YoY
+72.6%
EPS YoY
+34.0%
Gross Margin
-
Op Margin
-52.5%
Net Debt
-$225.75M
Current Ratio
6.94
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology